Trials / Conditions / Ovarian Mucinous Cystadenocarcinoma

Ovarian Mucinous Cystadenocarcinoma

21 registered clinical trials studyying Ovarian Mucinous Cystadenocarcinoma.

Status	Trial	Sponsor	Phase
Active Not Recruiting	Gemcitabine Hydrochloride With or Without WEE1 Inhibitor MK-1775 in Treating Patients With Recurrent Ovarian, NCT02101775	National Cancer Institute (NCI)	Phase 2
Active Not Recruiting	TORC1/2 Inhibitor MLN0128 and Bevacizumab in Treating Patients With Recurrent Glioblastoma or Advanced Solid T NCT02142803	National Cancer Institute (NCI)	Phase 1
Completed	Vaccine Therapy for Patients With Stage IIIC-IV Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cavi NCT02111941	Mayo Clinic	EARLY_Phase 1
Withdrawn	Acetyl-L-Carnitine Hydrochloride in Preventing Peripheral Neuropathy in Patients With Recurrent Ovarian Epithe NCT01492920	Gynecologic Oncology Group	Phase 3
Terminated	Granisetron, Aprepitant, and Dexamethasone in Preventing Nausea and Vomiting in Patients Receiving Chemotherap NCT01275664	Gynecologic Oncology Group	N/A
Completed	TLR8 Agonist VTX-2337 and Pegylated Liposomal Doxorubicin Hydrochloride or Paclitaxel in Treating Patients Wit NCT01294293	Gynecologic Oncology Group	Phase 1
Active Not Recruiting	Carboplatin and Paclitaxel or Oxaliplatin and Capecitabine With or Without Bevacizumab as First-Line Therapy i NCT01081262	National Cancer Institute (NCI)	Phase 3
Terminated	Veliparib, Oxaliplatin, and Capecitabine in Treating Patients With Advanced Solid Tumors NCT01233505	National Cancer Institute (NCI)	Phase 1
Completed	Intraperitoneal Bortezomib and Carboplatin in Treating Patients With Persistent or Recurrent Ovarian Epithelia NCT01074411	National Cancer Institute (NCI)	Phase 1
Completed	Changes in Brain Function in Patients With Stage I, Stage II, Stage III, or Stage IV Ovarian, Primary Peritone NCT01080521	Gynecologic Oncology Group	—
Completed	Belinostat and Carboplatin in Treating Patients With Recurrent or Persistent Ovarian Epithelial Cancer, Fallop NCT00993616	National Cancer Institute (NCI)	Phase 2
Completed	A6 in Treating Patients With Persistent or Recurrent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Prim NCT00939809	Gynecologic Oncology Group	Phase 2
Completed	Cisplatin and Paclitaxel in Treating Patients With Stage IIB, Stage IIC, Stage III, or Stage IV Ovarian Epithe NCT00814086	Gynecologic Oncology Group	Phase 1
Completed	Sargramostim and Paclitaxel Albumin-Stabilized Nanoparticle Formulation in Treating Patients With Advanced Ova NCT00466960	University of Washington	Phase 2
Completed	Denileukin Diftitox Used in Treating Patients With Advanced Refractory Ovarian Cancer, Primary Peritoneal Carc NCT00357448	University of Washington	Phase 1
Completed	Paclitaxel, Bevacizumab And Adjuvant Intraperitoneal Carboplatin in Treating Patients Who Had Initial Debulkin NCT00079430	National Cancer Institute (NCI)	Phase 1
Completed	Carboplatin and Paclitaxel With or Without Bevacizumab Compared to Docetaxel, Carboplatin, and Paclitaxel in T NCT00085358	National Cancer Institute (NCI)	Phase 1
Completed	Erlotinib Plus Carboplatin and Paclitaxel in Ovarian Carcinoma NCT00059787	National Cancer Institute (NCI)	Phase 2
Completed	Polyglutamate Paclitaxel and Carboplatin in Treating Patients With Ovarian Epithelial, Peritoneal, or Fallopia NCT00060359	Gynecologic Oncology Group	Phase 1
Terminated	Combination Chemotherapy and Peripheral Stem Cell Transplantation in Treating Patients With Stage III Ovarian NCT00004221	Gynecologic Oncology Group	Phase 2
Completed	Paclitaxel, Cisplatin, and Topotecan With or Without Filgrastim in Treating Patients With Newly Diagnosed Stag NCT00002913	National Cancer Institute (NCI)	Phase 1